Drug Trial Radar · NCT04023227
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
922
Actual
Start
Dec 10, 2019
Primary completion
Mar 16, 2025
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the effect of sacubitril/valsartan 200 mg BID compared with enalapril 10 mg BID, in addition to conventional heart failure (HF) treatment, in improving a hierarchical composite of cardiovascular (CV) events (i.e. CV death or the occurrence of first HF hospitalization) and causing a greater reduction in n terminal prohormone of brain natriuretic peptide (NT-proBNP, at Week 12 from Baseline) in participants with HF with reduced ejection fraction (HFrEF) caused by chronic Chagas' cardiomyopathy (CCC).
Conditions
- Chagas Disease
- Heart Failure
Interventions
Sacubitril/valsartanDrug
Participants randomized to sacubitril/valsartan who were previously treated with angiotensin-converting enzyme inhibitors (ACEIs) had a 36-hour washout prior to receiving oral treatment with 50, 100, or 200 mg, film-coated tablets.
EnalaprilDrug
Oral treatment with 5 or 10 mg tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From Baseline to Week 12Time frame: Total follow-up time up to approximately 36 months
- Percentage of Participants Who Died From Cardiovascular CausesTime frame: Total follow up time up to approximately 36 months
- Percentage of Participants With First Hospitalization for Worsening Heart FailureTime frame: Total follow up time up to approximately 36 months
- Change From Baseline to Week 12 in NT-proBNP LevelsTime frame: Baseline to Week 12
Locations
79 sites in 4 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Corrientes, Argentina
Novartis Investigative Site
Formosa, Argentina
Novartis Investigative Site
Formosa, Argentina
Novartis Investigative Site
Mendoza, Argentina
Novartis Investigative Site
Santa Fe, Argentina
Novartis Investigative Site
Santa Fe, Argentina
Novartis Investigative Site
Santiago del Estero, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Ramos Mejía, Buenos Aires, Argentina
Novartis Investigative Site
San Martín, Buenos Aires, Argentina
Novartis Investigative Site
Temperley, Buenos Aires, Argentina
Novartis Investigative Site
Villa María, Córdoba Province, Argentina
Novartis Investigative Site
Salta, Salta Province, Argentina
Novartis Investigative Site
San Miguel de Tucumán, San Miguel de Tucuman, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
San Miguel Tucuman, Tucumán Province, Argentina
Novartis Investigative Site
San Miguel Tucuman, Tucumán Province, Argentina
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Brasila, Federal District, Brazil
Novartis Investigative Site
Brasília, Federal District, Brazil
Novartis Investigative Site
Brasília, Federal District, Brazil
Novartis Investigative Site
Goiânia, Goiás, Brazil
Novartis Investigative Site
Goiânia, Goiás, Brazil
Novartis Investigative Site
Goiânia, Goiás, Brazil
Novartis Investigative Site
São Luís, Maranhão, Brazil
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.